Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Association of Enterococcus faecalis and tyrosine decarboxylase gene levels with levodopa pharmacokinetics in Parkinson’s disease

18 Mar 2025

Abstract excerpt

Multiple factors affect the absorption of orally administered levodopa, the gold standard for the treatment of Parkinson's disease (PD). Enterococcus faecalis (E. faecalis) expresses the enzyme tyrosine decarboxylase (tyrDC), which metabolizes levodopa into dopamine and thereby may influence its absorption in patients with PD. This study investigated the association between fecal E. faecalis and tyrDC gene levels...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Neurological diseases and metabolism
Share to Parkinson's Disease Mechanisms and Treatments
Share to RNA regulation and disease

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40102479
DOI: 10.1038/s41531-025-00903-6

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Association of Enterococcus faecalis and tyrosine decarboxylase gene levels with levodopa pharmacokinetics in Parkinson’s diseasePMID 40102479Read ↗

A review of studies on gut microbiota and levodopa metabolismSemantic proximity Read ↗

Gut bacterial tyrosine decarboxylase gene abundance associates with disease duration, medication exposure, and gastrointestinal symptoms in a longitudinal cohort of Parkinson’s disease patientsSemantic proximity Read ↗

Relationship Between Gut Bacteria and Levodopa MetabolismSemantic proximity Read ↗

High Throughput Assessment of Gut Bacterial Tyrosine Decarboxylase Activity for Predicting Peripheral Levodopa Loss in Parkinson's DiseaseSemantic proximity Read ↗

Gut microbiota and metabolome distinctive features in Parkinson disease: Focus on levodopa and levodopa‐carbidopa intrajejunal gelSemantic proximity Read ↗

Implications of Parkinson’s disease-associated alterations in the oral and gut microbiome on vitamin B12 biosynthesis and levodopa bioavailabilitySemantic proximity Read ↗

Functional implications of microbial and viral gut metagenome changes in early stage L-DOPA-naïve Parkinson’s disease patientsSemantic proximity Read ↗

Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiotaSemantic proximity Read ↗

Clinical Phenotypes of Parkinson's Disease Associate with Distinct Gut Microbiota and Metabolome Enterotypes.Semantic proximity Read ↗

Analysis of Gut Microbiota in Patients with Parkinson’s DiseaseSemantic proximity Read ↗

Gut microenvironmental changes as a potential trigger in Parkinson’s disease through the gut–brain axisSemantic proximity Read ↗

Microbial Diversity in Drug Naïve Parkinson’s Disease PatientsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.